| Literature DB >> 17016487 |
G K Atkin1, F M Daley, S Bourne, R Glynne-Jones, J M A Northover, G D Wilson.
Abstract
The goal of targeted therapy has driven a search for markers of prognosis and response to adjuvant therapy. The surgical resection of a solid tumour induces tissue ischaemia and acidosis, both potent mediators of gene expression. This study investigated the impact of colorectal cancer (CRC) surgery on prognostic and predictive marker levels. Tumour expression of thymidylate synthase, thymidine phosphorylase, cyclin A, vascular endothelial growth factor (VEGF), carbonic anhydrase-9, hypoxia inducible factor-1alpha, and glucose transporter-1 (GLUT-1) proteins was determined before and after rectal cancer surgery. Spectral imaging of tissue sections stained by immunohistochemistry provided quantitative data. Surgery altered thymidylate synthase protein expression (P=0.02), and this correlated with the change in the proliferation marker cyclin A. The expression of hypoxia inducible factor-1alpha, VEGF, and GLUT-1 proteins was also different following surgery. Colorectal cancer surgery significantly impacts on intratumoral gene expression, suggesting archival specimens may not accurately reflect in situ marker levels. Although rectal cancer was the studied model, the results may be applicable to any solid tumour undergoing extirpation in which molecular markers have been proposed to guide patient therapy.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17016487 PMCID: PMC2360543 DOI: 10.1038/sj.bjc.6603362
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Markers studied, and conditions for immunohistochemistry
|
|
|
|
|
|---|---|---|---|
| Thymidylate synthase (TS) | 4 × 4 min microwave in citric acid with 10 min standing | 1/300 | Simon Joel, London, UK |
| Cyclin A | 3 × 4 min microwave in citric acid with 10 min standing | 1/100 | #NCL-CYCLIN A, Novocastra Labs Ltd, UK |
| Thymidine phosphorylase (TP) | None | 1/400 | #MS-499-P0, NeoMarkers Inc., USA |
| Carbonic anhydrase-9 (CA-9) | None | 1/50 | Adrian Harris, Oxford, UK |
| Glucose transporter-1 (GLUT-1) | 3 × 4 min microwave in citric acid with 10 min standing | I/200 | #A3536, DAKO Corporation, USA |
| Hypoxia inducible factor-1 | 4 × 4 min microwave in citric acid with 20 min standing | 1/1000 | #ab463-100, Abcam Ltd, UK |
| Vascular endothelial growth factor (VEGF) | 3 × 4 min microwave in Tris-HCl with 10 min standing | 1/100 | #MS-350-P1, NeoMarkers Inc., USA |
Data for patients included in the analysis
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 1 | 77 | F | 13 | T3 N0 | 26 | 15 |
| 2 | 72 | M | 10 | T3 N2 | 49 | 3 |
| 3 | 58 | M | 15 | T2 N0 | 140 | 125 |
| 4 | 64 | M | 10 | T3 N1 | 65 | 60 |
| 5 | 74 | F | 15 | T4 N2 | 70 | 35 |
| 6 | 60 | M | 10 | T3 N0 | 75 | 15 |
| 7 | 59 | M | 15 | T3 N2 | 125 | 60 |
| 8 | 80 | M | 5 | T3 N0 | 70 | 20 |
| 9 | 57 | M | 13 | T3 N1 | 80 | 55 |
| 10 | 71 | F | 15 | T3 N0 | 38 | 20 |
| 11 | 62 | M | 14 | T3 N0 | 60 | 25 |
| 12 | 77 | M | 12 | T2 N0 | 120 | 55 |
| 13 | 63 | M | 2 | T2 N1 | 75 | 23 |
| 14 | 86 | F | 13 | T3 N0 | 50 | 25 |
| 15 | 49 | F | 14 | T2 N0 | 90 | 65 |
| 16 | 82 | F | 3 | T3 N1 | 65 | 15 |
| 17 | 68 | F | 12 | T3 N0 | 55 | 20 |
| 18 | 71 | M | 10 | T3 N0 | 55 | 15 |
| 19 | 78 | M | 15 | T3 N0 | 130 | 70 |
| 20 | 76 | F | 5 | T3 N2 | 80 | 45 |
| 21 | 68 | M | 13 | T3 N0 | 70 | 35 |
| 22 | 64 | M | 15 | T3 N0 | 85 | 45 |
| 23 | 77 | M | 15 | T3 N0 | 50 | 35 |
| 24 | 55 | M | 14 | T4 N2 | 100 | 15 |
| Median | 69.5 | 13 | 70 | 30 | ||
| Range | 49–86 | 2–15 | 26–140 | 3–125 |
Figure 1Overall changes in marker stain intensity ((A) arbitrary units, a.u.) and area (B) following surgery (error bars denote s.e.).
Figure 2Correlation between changes in TS stain intensity (a.u.) and duration of ischaemia ((A) rs=0.12, P=0.58) and extirpation ((B) rs=0.06, P=0.77).
Figure 3The changes in TS visual stain intensity (A) and area (B) scores occurring during CRC surgery. The length and the bearing of the arrows represent the magnitude and direction of the change in TS expression between pre- and postoperative biopsies.
Spectral stain intensity and area limits for each visual grade (visual intensity score represents overall TS stain intensity, visual area score denotes the percentage of the section staining positively for TS)
|
|
|
|
|
|
|---|---|---|---|---|
| Visual intensity score | Negative | Weak | Moderate | Strong |
| Spectral intensity range (a.u.) | 0 | 0.53–0.66 | 0.75–0.88 | 0.91–1.11 |
| Visual area score | <20% | 20–50% | 50–75% | >75% |
| Spectral area range (pixels × 105) | 0.02–1.1 | 1.7–2.4 | 2.5–3.1 | 3.7–4.0 |